[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-system-atrophy-msa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-system-atrophy-msa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,74,96,122,145,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637666","phase-1-a-study-to-evaluate-satety-tolerability-biodistribution-radiation-dosimetry-and-pharmacokinetics-of-sst001-in-healthy-volunteers-patients-with-pd-and-patients-with-msa-100637666",false,"NCT07604116","A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA","A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Sign the informed consent form approved by IEC.\n* Male or female participants aged ≥40 years old.\n* Adequate organ functions.\n* Proper contraception methods.\n* Willingness to follow the study procedures.\n* Additional inclusion criteria for healthy volunteers: Good health status; no history of motor disorders or cognitive disorders.\n* Additional inclusion criteria for MSA: Diagnosed with clinically established or clinically probable MSA according to the MDS MSA criteria (2022). If previously treated, the treatment regimen for MSA must have been stable for at least 4 weeks with no planned adjustments in the near term.\n* Additional inclusion criteria for PD: Diagnosed with clinically established or clinically probable PD according to the MDS PD criteria (2015). If previously treated, the treatment regimen for PD must have been stable for at least 4 weeks with no planned adjustments in the near term.\n\nExclusion Criteria:\n\n* Being pregnant or lactating.\n* History of other severe neurological disorders.\n* History of serious or uncontrolled medical condition.\n* Active HBV\u002FHCV\u002FHIV infection, etc.\n* History of abuse of drugs or alcohol within 1 year.\n* Allergy to the study drug.\n* Intolerance to PET\u002FCT or MRI (e.g. claustrophobia).\n* Any interventional clinical studies within 30 days.\n* Radiation exposure dose exceeding 50 mSv\u002Fyear.\n* Prior therapy targeting α-Syn.\n* Other ineligible conditions for this study.",true,"ALL","40 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.",[27,28],"Multiple System Atrophy (MSA)","Parkinson's Disease (PD)","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2026-06-15",{"date":37,"type":21},"2027-02",{"name":39,"class":40},"Synusight Biotech (Shanghai) Co., Ltd.","INDUSTRY",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100642604","early-phase-1-evaluation-of-fmodag-009-pet-imaging-in-synucleinopathies-100642604","NCT07640555","Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies","MODAG-009-P1-0","Inclusion Criteria:\n\n* Healthy Controls inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a healthy control participant\n  2. Any gender aged 50 to 75 years of age\n  3. Negative CSF α-synuclein seed amplification assay (SAA)\n  4. Previously acquired (since inclusion in PPMI) brain MRI without evidence of significant neurological pathology.\n  5. Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score of \\\u003C6 at the last PPMI annual visit which is within the past 18 months.\n  6. Cognitively intact with Montreal Cognitive Assessment (MoCA) greater than or equal to 26 at the last PPMI annual visit which was within the past 18 months.\n* Parkinson's Disease and Prodromal PD inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a Parkinson's Disease (PD) or Prodromal participant\n  2. Any gender aged 50 to 80 years of age\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms for PD or since enrolled in PPMI for the prodromal PD) without evidence of significant neurological pathology other than changes expected for PD.\n  5. Montreal Cognitive Assessment (MoCA) greater than or equal to 24 at the last PPMI annual visit which was within the past 18 months.\n* Multiple System Atrophy (MSA) inclusion criteria:\n\n  1. Any gender aged 50 to 75 years of age\n  2. Clinically established MSA or Clinically Probable MSA according to the Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (Wenning et al., 2022)\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms attributed to MSA) without evidence of significant neurological pathology other than the pathology expected for MSA.\n  5. Evidence of nigrostriatal degeneration on DaTscan obtained at screening or on previously acquired imaging since the onset of the motor symptoms attributed to MSA.\n\nExclusion Criteria:\n\n* All Cohorts:\n\n  1. Clinical evidence of other neurodegenerative diseases, such as Alzheimer's disease\n  2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n  3. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide, lithium and reserpine, within 6 months of Baseline Visit.\n  4. Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment.\n  5. Participation in an investigational drug trial targeting α-synuclein within the past 6 months prior to enrollment.\n  6. Currently being treated with and unable to safely hold antiplatelets (other than low dose aspirin up to 100mg\u002Fday) or anticoagulants prior to the procedure that might preclude safe attempt of Lumbar puncture, if applicable.\n  7. Condition that precludes the safe performance of routine lumbar puncture, if applicable, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant and uncorrected coagulopathy or thrombocytopenia.\n  8. Conditions or medications that preclude safe performance of imaging procedures (MRI or DaTscan), including but not limited to severe claustrophobia, MRI-incompatible metal implants, or known hypersensitivity to imaging agents.\n  9. Known hypersensitivity to DaTscan or iodine-containing compounds used as premedication for DaTscan. Participants with iodine sensitivity may still complete the imaging without iodine premedication at the investigator's discretion.\n  10. Use of medications known to interfere with DaTscan imaging (e.g., bupropion, amphetamines, methylphenidate, modafinil, alpha-methyldopa), unless the participant is willing and medically able to hold the medication for at least 5 half-lives or specified duration per investigators judgement prior to imaging.","50 Years","80 Years",{"count":52,"type":21},13,[54],"EARLY_PHASE1","This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \\[¹⁸F\\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of \\[¹⁸F\\]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.",[27,57,58],"Healthy Adult","Parkinson Disease",[60,61,62,63,64],"MODAG","MODAG GmbH","MODAG-009","PET Tracer","Synuclein","2026-06-06",{"date":67,"type":33},"2026-06-10",{"date":69,"type":33},"2026-05-13",{"date":71,"type":21},"2027-05",{"name":61,"class":40},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":73},"100348056","multiple-system-atrophy-multidisciplinary-clinic-100348056","NCT03811808","Multiple System Atrophy Multidisciplinary Clinic","Inclusion Criteria:\n\n* Subject must be a patient in the UT Southwestern MSA clinic and be able to attend the multidisciplinary clinic every 4 months\n* Patients with possible or probable MSA based on established criteria\n* Subjects must be 18 years or older\n\nExclusion Criteria:\n\n* Patients that are unable to give consent\n* Minor patients (younger than age 18)\n* Non-English speaking patients\n* Subjects that are diagnosed with dementia","18 Years",{"count":82,"type":21},200,"OBSERVATIONAL","This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden. Data will be collected through valid rating scales completed by patients and caregivers at home or in the MSA clinic.",[27],"2026-05-19",{"date":88,"type":33},"2026-05-22",{"date":90,"type":4},"2016-03",{"date":92,"type":21},"2028-03",{"name":94,"class":95},"University of Texas Southwestern Medical Center","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100627304","phase-3-msa-01-in-multiple-system-atrophy-100627304","NCT07446894","MSA-01 in Multiple System Atrophy","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of MSA-01 in Patients With Multiple System Atrophy","MSA-01_P3","Inclusion Criteria:\n\nAt the time of informed consent\n\n1. Patients diagnosed as 'clinically established' or 'clinically probable' MSA based on the revised MSA diagnostic criteria of the Movement Disorder Society (MDS).\n2. Patients who are able to walk independently or with the use of assistive devices.\n3. Patients who are able to attend outpatient visits at the participating study site.\n\n   At the start of study drug administration\n4. Patients who are able to discontinue the use of CoQ10 supplements.\n\nExclusion Criteria:\n\n1. Patients with severe neurological disorders, other progressive movement disorders, or cognitive impairment.\n2. Patients with severe liver disease.\n3. Patients with a known history of hypersensitivity to any component of the investigational drug.\n4. Pregnant women, breastfeeding women, or women who may be pregnant.\n5. Patients who have previously participated in a clinical trial of MSA-01.","30 Years","79 Years",{"count":107,"type":21},140,[109],"PHASE3","The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety.\n\nThe primary question is:\n\n• Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score?\n\nParticipants will be randomly assigned to receive MSA-01 or placebo for 12 months. They will attend regular clinic visits for safety and efficacy assessments and record their medication use and any side effects in a diary.",[27],"2026-03-02",{"date":114,"type":33},"2026-03-04",{"date":116,"type":33},"2026-02-09",{"date":118,"type":21},"2028-03-31",{"name":120,"class":95},"Tokyo University",12,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":16,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":73},"100584619","early-phase-1-18faci-15916-pet-in--synucleinopathies-100584619","NCT06891703","[18F]ACI-15916 PET in α-synucleinopathies","Phase 1 Study to Evaluate [18F]ACI-15916 as a Potential PET Radioligand for Imaging α-synuclein Deposits in the Brain of Patients With Suspected α-synuclein Pathology Compared With Healthy Volunteers","Inclusion Criteria for all Participants:\n\n1. Subject is able to provide written informed consent, which must be obtained before any assessment is performed.\n2. Subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements.\n3. Body mass index is \\> 18 and \\\u003C 31 kg\u002Fm2 and Bodyweight ≥ 50 kg and ≤ 100 kg.\n4. Female participants must not be of childbearing potential or agree to use highly effective methods of contraception.\n5. For subjects receiving arterial cannulation, an adequate circulation to the hand for safe placement of arterial line (as determined by Allen's test).\n\n   Additional Inclusion Criteria for Healthy Volunteers:\n6. Males and females aged ≥ 20 at the time of signing the informed consent.\n7. Normal MRI and DAT PET or SPECT (except for Part 4 participants), as judged by the investigator.\n8. The subject is, in the opinion of the investigator, generally healthy based on the assessment of medical history, physical examination, vital signs, ECG, and the results of the hematology, clinical chemistry, urinalysis, serology, and other laboratory tests.\n9. No family history of α-synucleinopathy, including PD, or other early-onset neurological disease associated with dementia.\n10. No personal history of clinically significant neurologic and\u002For psychiatric disorders.\n11. Have a Montreal Cognitive Assessment (MoCA) score ≥ 26\n12. No cognitive impairment as judged by the PI or delegated physician.\n\n    Additional Inclusion Criteria for Participants with α-synucleinopathies:\n13. Males and females aged ≥ 40 at the time of signing the informed consent.\n14. Subjects diagnosed with any of the following:\n\n    * Idiopathic PD based on MDS criteria\n    * PD with genetic risk factor (except some mutations as mentioned in exclusion criteria)\n    * Dementia with Lewy bodies (DLB)\n    * Diagnosis of possible or probable Multiple System Atrophy (MSA)\n15. Evidence of dopamine transporter deficit on DAT PET or SPECT imaging performed either as part of Screening or previously acquired (if not older than 6 months) and of good quality as judged by the investigator.\n16. Medications taken for symptomatic treatment of α-synucleinopathy must be maintained on a stable dosage regimen for at least 30 days before the Screening Visit.\n\nExclusion Criteria for all Participants:\n\n1. Female subjects pregnant, lactating or breastfeeding.\n2. Presence of psychiatric symptoms that may interfere with the objectives of the study, as judged by the investigator.\n3. Clinically significant concomitant disease or condition within 6 months prior to screening, that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant, or compromise the scientific quality of the study.\n4. History of brain surgery or any neurosurgical procedures. Subject has received treatment with a drug, antibody or vaccine targeting α-synuclein.\n5. Known or suspected drug, alcohol or other abuse, or positive urine drug screen which may interfere with the study objective, as judged by the investigator.\n6. History of severe allergy\u002Fhypersensitivity or ongoing allergy\u002Fhypersensitivity as judged by the investigator.\n7. Subject is involved in the planning and\u002For conduct of the study (i.e. part of the study team)\n8. History of clinically significant cardio-or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder or any other major disorder that may interfere with the objectives of the study, as judged by the investigator.\n9. History of and\u002For screening brain MRI scan (except for Part 4 subjects) indicative of, clinically significant abnormality including but not limited to prior haemorrhage or infarct or \\>3 lacunar infarcts, except changes consistent with α-synucleinopathies for PD, MSA, DLB patients.\n10. Subjects being treated with any anticoagulants or antiplatelet drugs, except aspirin at doses of 100 mg daily or lower within 2 weeks of the planned arterial cannula placement (if performed) for either the baseline or retest imaging.\n11. Screening supine blood pressure \\> 150 mm Hg (systolic) or \\> 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If blood pressure (BP) is \\> 150 mm Hg (systolic) or \\> 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.\n12. Electrocardiographic (ECG) abnormalities of clinical significance as judged by the investigator. Screening supine 12-lead ECG demonstrating QTc \\> 450 msec at Screening.\n13. Any contraindications to obtaining a brain MRI (except for Part 4 subjects), DaT-SPECT (except for Part 4 subjects) or PET (e.g., claustrophobia unresponsive to reassurance or low dose of an anxiolytic agent, metal implants not compatible with MRI or known hypersensitivity to the active substance or to any of the excipients) and ability to tolerate lying in the scanner for up to \\~180 minutes.\n14. Previous exposure to radiation for medical, scientific or other reasons which could have a high negative impact on the research subject, as judged by the investigator.\n15. Treatment with any other investigational therapy within 5 drug elimination half-lives or 30 days (whichever is longer) prior to inclusion in the study.\n\n    Additional Exclusion Criteria for Healthy Volunteers:\n16. Current use of CNS active drugs, including antidepressant or neuroleptic medications is not permitted, anti-inflammatory drugs or sleep medications may be allowed at the discretion of the investigator.\n17. History of neurological disease\u002Fcondition that may interfere with the objectives of the study, as judged by the investigator.\n\n    Additional Exclusion Criteria for Participants with α-synucleinopathy:\n18. Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including but not limited to, progressive supranuclear palsy, drug-induced parkinsonism, essential tremor, vascular parkinsonism, primary dystonia or corticobasal syndrome (CBS).\n19. Known carriers of certain familial PD gene mutations (PRKN, PINK1, DJ1, LRRK2), based on previous source documentation.","20 Years",{"count":131,"type":21},46,[54],"The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein \\[involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple System Atrophy (MSA), collectively named α-synucleinopathies\\] using a new positron emission tomography (PET) tracer called \\[18F\\]ACI-15916. Both healthy people and people with (suspected) α-synuclein pathology will participate to this trial.\n\nThe main questions it aims to answer are:\n\n* whether \\[18F\\]ACI-15916 is safe and well tolerated when injected into participants\n* whether \\[18F\\]ACI-15916 reliably detects α-synuclein in the brain using PET technique.\n* whether there are differences in the amount of this protein between people with diseases related to α-synuclein accumulation in the brain and people without these diseases.\n\nParticipants will:\n\n* Visit the clinic to consent to their participation and to ensure they are eligible \\[physical and neurological examinations, questionnaires, blood and urine tests, ECG and in some cases a MRI and a PET scan with a licensed tracer (\\[18F\\]FE-PE2I) to confirm or not the disease\\].\n* Visit the clinic to receive the tracer \\[18F\\]ACI-15916 intravenously and be scanned in a PET scanner, during which blood will be collected (and optionally spinal fluid).\n* Receive a phone call from the clinic 1 week after the PET scan to report any symptoms and side-effects that they may be having.\n\nSome of the participants may be asked to come again to the clinic for a second PET scan with \\[18F\\]ACI-15916, allowing the researchers to determine if the measurements with the first PET scan are stable and reproducible.\n\nSome of the participants will participate in a specific part of the study to evaluate the distribution of the PET ligand in the whole body, with a similar visit schedule.",[28,27,135],"Dementia With Lewy Bodies (DLB)","2025-11-18",{"date":138,"type":33},"2025-11-19",{"date":140,"type":33},"2025-03-20",{"date":142,"type":21},"2026-03",{"name":144,"class":40},"AC Immune SA",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":73},"100574934","early-phase-1-the-study-of-safety-and-preliminary-efficacy-of-aleeto-in-patients-with-multiple-system-atrophy-100574934","NCT06765733","The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy","SPRITE","Inclusion Criteria:\n\n1.30 years ≤ 75 years of age, regardless of sex; 2.Clinically confirmed or clinically probable MSA-P; 3.Poor response to levodopa; 4.MSA-related motor symptom onset ≤5 years at first visit; 5.Walking ≥10 meters independently or with a walking aid; 6.Expected survival of ≥1 year, as determined by the investigator; 7.Signed informed consent.\n\nExclusion Criteria:\n\n1. Head MRI at screening showing evidence of other CNS lesions consistent with a diagnosis of neurodegenerative disease other than MSA;\n2. Patients with MMSE scores indicative of dementia prior to enrolment (≤17 points for illiterate individuals, ≤20 points for individuals with elementary school education, ≤24 points for individuals with junior high school education or higher) or those with a prior confirmed diagnosis of dementia;\n3. Head MRI at screening showing other significant pathological findings including but not limited to: cerebral hemorrhage, acute phase of cerebral infarction, aneurysm, vascular malformation, infectious lesion, brain tumor or other space-occupying lesion (meningiomas or arachnoid cysts with a maximum diameter of \\\u003C1 cm need not be excluded);\n4. Presence of immune disorders that are inadequately controlled or require treatment with biological agents;\n5. Known history of allergy to biological agents such as proteins and cell products;\n6. Patients who have received any vaccination within 1 month;\n7. Patients with pre-existing, clearly diagnosed malignant tumor or being treated with anti-tumor drugs;\n8. Patients with a history of clearly diagnosed epilepsy or taking antiepileptic drugs;\n9. Presence of lumbar spine disease and deformity or other contraindications to lumbar puncture;\n10. Patients with abnormal coagulation function prior to enrolment (e.g., platelet count \\\u003C100 × 10E9\u002FL; prothrombin time \\[PT\\] \\>3 s), previous diagnosis of coagulation disorders such as hemophilia, and patients currently receiving more than two types of antiplatelet medication;\n11. Contraindications to MRI (e.g. claustrophobia, internal placement of pacemakers or paramagnetic metals, etc.);\n12. With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR\\\u003C40mL\u002Fmin\u002F1.73m2; severe cardiac insufficiency refers to NYHA class 3-4);\n13. Hepatitis B active infection (hepatitis B surface antigen positive and\u002For serum HBV DNA positive or serum HBV DNA \\> 2 × 10E8 IU\u002Fml;\n14. Hepatitis C virus antibody positive or history of positive test;\n15. Positive HIV test or history of positive test;\n16. Patients with a combined history of alcohol or drug abuse or alcohol or drug dependence within 2 years;\n17. Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent;\n18. Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant;\n19. Patients who are participating in other interventional studies or using other investigational biological agents, drugs, or devices, and patients who have used other experimental drugs within 1 month or within 5 drug half-lives;\n20. Unable to be cooperative and complete the follow-up due to other reasons.\n21. Patients who, in the opinion of the investigator, are not suitable for participation in this trial.","75 Years",{"count":154,"type":21},20,[54],"This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).",[158,159],"Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, MSA",[161,162,163,164],"Multiple System Atrophy","Treatment","Exosomes","Neurorepair","2025-08-30",{"date":167,"type":33},"2025-09-03",{"date":169,"type":33},"2025-05-31",{"date":171,"type":21},"2026-12-31",{"name":173,"class":95},"Beijing Tiantan Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":152,"enrollmentInfo":181,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":73},"100589088","ai-enhanced-optimization-of-acute-levodopa-challenge-test-100589088","NCT06949865","AI-Enhanced Optimization of Acute Levodopa Challenge Test","Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence","Inclusion Criteria:\n\n1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.\n2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.\n6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Cognitive dysfunction, unable to complete the study (MMSE \\\u003C 23)\n2. Inability to tolerate levodopa shock test\n3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases\n4. Those with serious behavioral problems or mental disorders\n5. Inability to sign informed consent\n6. Other conditions that are considered unsuitable by the investigator to participate in this study.",{"count":182,"type":21},2000,"A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.",[185,186,187,188,189,190,27],"Vascular Parkinsonism","Drug-induced Parkinsonism","Corticobasal Degeneration (CBD)","Parkinson Disease (PD)","Dementia With Lewy Body Disease","Progressive Supranuclear Palsy(PSP)","2025-04-22",{"date":193,"type":33},"2025-04-29",{"date":195,"type":33},"2024-05-28",{"date":171,"type":21},{"name":173,"class":95}]